Author Login

Correspondence to Author: Lauera-Maria Krawbbe, Georgidsos Gakis, Yaeir Lotan  

The University of Muenster Medical Center, Germany

Introduction: An estimated 550000 cases of bladder cancer are diagnosed globally each year, and the disease is thought to be the cause of about 200000 fatalities. Bladder cancer is one of the most costly cancers to treat because it requires regular follow-up, invasive procedures like cystoscopy, repetitive procedures like transurethral resection of bladder tumors and intravesical instillation therapy in non-muscle invasive stages, and systemic treatment with or without radical local treatment in advanced stages. The treatment algorithms for bladder cancer could be drastically altered by prognostic and predictive biomarkers, which could lead to better oncological outcomes and patient comfort as well as a reduction in the disease’s socioeconomic burden. The first treatment for this illness that targets a particular mutation (fibroblast growth factor receptor) was just approved by the U.S. Food and Drug Administration as a result of extensive study. However, despite their therapeutic success, many aspects of bladder cancer diagnosis and treatment have not changed in decades. Particular concerns for the various illness phases and contexts should be kept in mind when integrating biomarkers into clinical practice patterns. (Urine-)biomarkers may be helpful, particularly in the context of screening, hematuria work-up, and patient surveillance for non-muscle invasive bladder cancer. However, they must exhibit a high enough sensitivity to detect a cancer diagnosis or recurrence and enable simple management. (ideally in a point-of-care context) and appropriate cost-benefit analyses, in addition to offering supplementary data for a comprehensive work-up. It would be very helpful to have a biomarker to identify individuals with muscle invasive bladder cancer who require neoadjuvant therapy and are likely to respond to it. Improved patient care in later stages of the disease will depend heavily on early diagnosis of progression or recurrence, as well as biomarkers that inform treatment choices among the current systemic medicines.

Keywords:Biomarkers, bladder cancer, muscle invasive bladder cancer, non-muscle invasive bladder cancer, neoadjuvant therapy, hematuria, cystoscopy, risk stratification, clinical decision-making.

Citation:

Lauera-Maria Krawbbe. Clinical Utility Of Bladder Cancer Biomarkers. Journal Of Cancer And Tumor Research 2025.